TRAW
insider transactionsTraws Pharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Chief Financial Officer
$0
104.5K sh
Own New
-
Grant·A
Director
$0
33.4K sh
Own New
-
Grant·A
Chief Operating Officer
$0
96.9K sh
Own New
-
Grant·A
Director
$0
33.4K sh
Own New
-
Grant·A
Chief Medical Officer
$0
108.9K sh
Own New
-
Grant·A
Chief Science Officer Virology
$0
118.4K sh
Own New
-
Grant·A
Director
$0
33.4K sh
Own New
-
Grant·A
Director
$0
33.4K sh
Own New
-
Grant·A
Director
$0
31.3K sh
Own New
-
Grant·A
Chief Financial Officer
$0
61.6K sh
Own New
-
Grant·A
Chief Financial Officer
$0
15.4K sh
Own New
-
Grant·A
Chief Financial Officer
$0
32.4K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 8, 2026 | Charles Nolan Parker KEY | Grant A | 104.5K | $0 |
| Mar 8, 2026 | Mary Teresa Shoemaker | Grant A | 33.4K | $0 |
| Mar 8, 2026 | Nikolay Savchuk | Grant A | 96.9K | $0 |
| Mar 8, 2026 | Jack E Stover | Grant A | 33.4K | $0 |
| Mar 8, 2026 | Robert Redfield | Grant A | 108.9K | $0 |
| Mar 8, 2026 | Charles David Pauza | Grant A | 118.4K | $0 |
| Mar 8, 2026 | John Harold Leaman | Grant A | 33.4K | $0 |
| Mar 8, 2026 | Trafford Clarke | Grant A | 33.4K | $0 |
| Mar 8, 2026 | Werner Cautreels | Grant A | 31.3K | $0 |
| Dec 12, 2025 | Charles Nolan Parker KEY | Grant A | 61.6K | $0 |
| Dec 12, 2025 | Charles Nolan Parker KEY | Grant A | 15.4K | $0 |
| Oct 12, 2025 | Charles Nolan Parker KEY | Grant A | 32.4K | $0 |
About TRAW insider trading
This page tracks insider transactions for Traws Pharma, Inc. (TRAW) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.